Clinical Trials
18
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Simplified Onboarding in Adults With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Insulet Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT07070830
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Insulet Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT07039981
- Locations
- 🇳🇿
University of Otago, Christchurch, Christchurch, New Zealand
🇳🇿Wellington Regional Hospital, Wellington, New Zealand
French Prospective Multicentric Study in Real World
- Conditions
- DiabetesDiabetes MellitusType 1 Diabetes
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Insulet Corporation
- Target Recruit Count
- 304
- Registration Number
- NCT07039942
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Besançon - Hôpital de Jean Minjoz, Besançon, France
🇫🇷APHP Hopital Avicenne, Bobigny, France
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 1, Type 2
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Insulet Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT06865989
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Sansum Diabetes Research Institute, Santa Barbara, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Insulet Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT06547918
- Locations
- 🇳🇿
University of Otago, Christchurch, Christchurch, New Zealand
🇳🇿Wellington Regional Hospital, Wellington, New Zealand
- Prev
- 1
- 2
- 3
- 4
- Next
News
Insulet Presents Real-World Evidence of Omnipod 5 Benefits in Type 2 Diabetes at ADA 2025
Insulet shared real-world glycemic outcomes data from over 23,000 people with type 2 diabetes using the Omnipod 5 automated insulin delivery system in the United States.
Visby Medical Secures $65 Million to Launch FDA-Authorized At-Home STI Test
Visby Medical raised approximately $55 million with potential to reach $65 million in funding led by Catalio Capital Management to accelerate launch of its FDA-authorized at-home Women's Sexual Health Test.
Global Diabetes Care Market Projected to Reach $62.73 Billion by 2032 Driven by Rising Disease Prevalence and Technology Advances
The global diabetes care market is expected to grow from $34.51 billion in 2025 to $62.73 billion by 2032, representing a compound annual growth rate of 8.9%.
Smart Drug Delivery Systems Market Poised for 17% Growth as Chronic Disease Management Evolves
The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.
FDA Approves Abbott's Coronary IVL System Trial for Treating Calcified Coronary Artery Disease
Abbott Laboratories has received FDA approval for an Investigational Device Exemption to evaluate its Coronary Intravascular Lithotripsy System in patients with severely calcified coronary artery disease.
Insulet Expands Omnipod 5 Automated Insulin Delivery System to Australia and Three Additional Markets
• Insulet's tubeless Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia and will soon launch in Belgium, Canada, and Switzerland, expanding access to thousands more diabetes patients globally. • The system integrates with continuous glucose monitors from Dexcom (G6 and G7) and Abbott's FreeStyle Libre 2 Plus, automatically adjusting insulin delivery every five minutes using SmartAdjust technology. • Insulet plans further expansion to five additional Middle Eastern markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, strengthening its global leadership position in automated insulin delivery technology.